Bioscientia Institut FÜR Medizinische Diagnostik GMBH

Bioscientia Institut FÜR Medizinische Diagnostik GMBH, doing business as Bioscientia Medizin. Labor. Service., is a for-profit medical diagnostics laboratory headquartered in Ingelheim am Rhein, Germany. The organization has been registered in SAM.gov since July 25, 2003, and maintains an active federal vendor registration expiring September 15, 2026. Bioscientia provides clinical reference laboratory testing services to support U.S. military healthcare operations in Europe, with expertise in comprehensive diagnostic capabilities including COVID-19 testing and other services that meet College of American Pathologists (CAP) standards.

Bioscientia has demonstrated consistent performance as a prime federal contractor exclusively with the Defense Health Agency, providing clinical reference laboratory testing services in support of the Landstuhl Regional Medical Center (LRMC) in Germany. The company has received six delivery orders issued between May 2022 and October 2025, with individual order values ranging from approximately $102,000 to $205,000, reflecting ongoing demand for its specialized laboratory testing capabilities. These delivery orders have been awarded without set-aside designations through full and open competition, indicating the vendor's ability to compete successfully in unrestricted federal procurements. All awards have been firm fixed-price delivery orders issued against underlying Indefinite Delivery Contracts, with no subcontracting partners identified in the available award documentation. The Defense Health Agency has been the sole funding agency across all delivery orders issued to Bioscientia, demonstrating a concentrated customer relationship focused on supporting U.S. military medical operations in the European theater.

Bioscientia currently holds two active Indefinite Delivery Contracts with the Defense Health Agency. The most recent IDC was awarded on May 1, 2025, with a ceiling value of $400,000 and a performance period extending through April 30, 2026, serving as the primary contracting vehicle for issuing delivery orders for local reference laboratory testing services at LRMC. The predecessor IDC, awarded May 1, 2022, carries a ceiling value of $690,476.25 with a performance period through April 30, 2025, and has been the source of multiple delivery orders demonstrating the sustained requirement for Bioscientia's laboratory testing services. Both single-award contracts were established through full and open competition without set-aside designations, and the delivery orders issued against these vehicles have ranged from approximately $90,600 to $205,400, reflecting flexible procurement of critical laboratory services essential to U.S. military healthcare missions in Europe.